| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Muscarinic acetylcholine receptor M4, CHRM4 |
| Entrez GeneID | 1132 |
| WB Predicted band size | 53.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This CHRM4 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 201-236 amino acids from human CHRM4. |
+ +
以下是关于CHRM4抗体的参考文献示例(注：内容为模拟虚构，仅供参考)：
1. **"CHRM4 Antibody Validation in Central Nervous System Studies"**
- **作者**: Smith A, et al.
- **摘要**: 研究验证了CHRM4抗体的特异性，通过免疫组化和Western blot技术确认其在啮齿类动物脑组织中的表达定位，发现其与突触后膜胆碱能信号传导密切相关。
2. **"Role of CHRM4 Autoantibodies in Autoimmune Neuropathies"**
- **作者**: Zhang L, et al.
- **摘要**: 探讨CHRM4自身抗体在罕见自身免疫性神经疾病中的作用，发现患者血清中的抗体可阻断受体功能，导致胆碱能神经信号异常。
3. **"CHRM4 Antibody-Based Targeting in Gastrointestinal Motility Disorders"**
- **作者**: Tanaka K, et al.
- **摘要**: 利用CHRM4抗体研究肠道平滑肌中该受体的分布，揭示其通过调节乙酰胆碱信号影响胃肠动力，为治疗功能性消化不良提供新思路。
4. **"Development of a Novel Monoclonal CHRM4 Antibody for Cancer Research"**
- **作者**: Patel R, et al.
- **摘要**: 报道一种高特异性单克隆CHRM4抗体的开发，并证明其在肺癌细胞系中可抑制受体介导的增殖信号通路，提示潜在治疗价值。
(提示：实际文献需通过PubMed、Google Scholar等平台检索确认。)
The CHRM4 antibody targets the cholinergic receptor muscarinic 4 (CHRM4), a G protein-coupled receptor (GPCR) that binds acetylcholine and mediates parasympathetic nervous system signaling. CHRM4 is one of five muscarinic receptor subtypes (M1-M5) and primarily couples to Gαi/o proteins, inhibiting adenylyl cyclase activity and reducing intracellular cAMP levels. It is expressed in the central nervous system, heart, smooth muscle, and exocrine glands, playing roles in cognitive function, cardiac rhythm regulation, and glandular secretion.
Antibodies against CHRM4 are widely used in research to study its expression, localization, and function in physiological and pathological contexts. They are critical tools for Western blotting, immunohistochemistry, and flow cytometry to explore CHRM4's involvement in diseases such as Alzheimer's, schizophrenia, cancer (e.g., glioblastoma, colorectal cancer), and cardiovascular disorders. Some studies suggest CHRM4 overexpression in certain tumors, highlighting its potential as a therapeutic target.
Commercial CHRM4 antibodies are typically raised against specific epitopes, such as extracellular or intracellular domains, and vary in clonality (monoclonal/polyclonal) and species reactivity. Validation includes testing in knockout models or tissue-specific expression systems to ensure specificity. Research using these antibodies has advanced understanding of CHRM4's signaling mechanisms, including its crosstalk with other receptors and pathways, aiding drug development for muscarinic receptor-related disorders.
×
